# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0....
Lantern Pharma Inc. (NASDAQ:LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, toda...
HC Wainwright & Co. analyst Emily Bodnar reiterates Lantern Pharma (NASDAQ:LTRN) with a Neutral.
never smokers – a growing and unaddressed patient population.Dr. Yashushi Goto a leading lung cancer clinician-scientist at the...